Antenatal Screening and Maternal-Fetal Assessment

Antenatal screening and maternal-fetal assessment is the set of tests and observations used during pregnancy to evaluate the health of the woman and the developing fetus and to identify conditions that may need further investigation. It spans routine maternal observations, laboratory and infection screening, screening for fetal chromosomal and structural conditions, and surveillance of fetal growth and wellbeing.

Definition

Antenatal screening is the offer of tests during pregnancy to estimate, in an asymptomatic population, the chance that the mother or fetus has a particular condition, so that further diagnostic assessment or care can be offered; maternal-fetal assessment is the broader monitoring of maternal and fetal wellbeing across pregnancy.

Scope

This topic covers the logic of screening in pregnancy and the main categories of antenatal assessment: maternal observations and history, laboratory and infection screening, glucose and blood-pressure surveillance, and screening tests for fetal aneuploidy and anomaly. It distinguishes screening (offered to a population to estimate risk) from diagnosis, and treats these as reference concepts rather than as a protocol for any individual pregnancy.

Core questions

• What distinguishes a screening test from a diagnostic test in pregnancy?
• Which maternal and fetal conditions are commonly screened for antenatally?
• How are fetal aneuploidy screening results interpreted as a risk rather than a diagnosis?
• How is fetal growth and wellbeing assessed across pregnancy?

Key concepts

• Screening versus diagnosis
• Sensitivity, specificity, and predictive value
• Combined and cell-free DNA aneuploidy screening
• Anomaly screening
• Maternal laboratory and infection screening
• Gestational diabetes and blood-pressure surveillance
• Fetal growth and wellbeing surveillance
• Informed choice and consent for screening

Mechanisms

Screening estimates risk in an asymptomatic population: a test divides those offered it into higher- and lower-probability groups, with performance characterised by sensitivity, specificity, and predictive value, and a positive screen prompting an offer of diagnostic testing rather than confirming a condition. Fetal aneuploidy screening has moved from biochemical and ultrasound markers toward analysis of cell-free DNA in maternal blood, which improves detection and lowers false-positive rates for common trisomies while remaining a screening rather than diagnostic test. Maternal-fetal surveillance combines observations, laboratory tests, and growth assessment to detect conditions such as anaemia, infection, hyperglycaemia, raised blood pressure, and impaired fetal growth.

Clinical relevance

Antenatal screening and assessment generate much of the information on which pregnancy care decisions are based, and understanding their interpretation is part of evidence appraisal for midwives and other clinicians. This entry describes how screening and assessment work and how their results should be read; it is not a protocol and does not direct testing or management for any individual woman.

Epidemiology

Programmes offer screening for fetal chromosomal conditions, structural anomalies, maternal infections, anaemia, and metabolic conditions such as gestational diabetes, whose definition is informed by observed continuous associations between maternal glucose and pregnancy outcomes. Cell-free DNA screening has higher detection and lower false-positive rates for common trisomies than standard biochemical-plus-ultrasound screening in general-risk populations.

History

Antenatal screening expanded through the late twentieth century from maternal observations and selected blood tests to structured fetal anomaly and aneuploidy programmes. Combined first-trimester screening using nuchal translucency and biochemistry was succeeded for many indications by cell-free DNA analysis after studies in general-risk populations demonstrated improved test performance.

Debates

How should cell-free DNA screening be positioned within programmes?

Cell-free DNA improves detection and reduces false positives for common trisomies, but it is a screening rather than diagnostic test, and its placement (first-line, contingent, or supplementary) and the counselling and consent it requires remain debated.

Seminal works

• bianchi-2014
• who-2016-anc

Frequently asked questions

Does a positive screening test mean the baby has the condition?

No. A screening test estimates the chance that a condition is present; a higher-risk result usually leads to an offer of diagnostic testing, which is what can confirm or exclude the condition.

Is antenatal screening compulsory?

Screening is offered, not imposed; informed choice and consent are central, and a woman may accept or decline the tests offered. This entry explains the concepts rather than recommending any particular test for an individual.